{"prompt": "['MC1575', '62', 'Amendment 2', 'Duffy, D. E. and T. J. Santner (1987). \"Confidence-Intervals for a Binomial Parameter Based on', \"Multistage Tests.' Biometrics 43(1): 81-93.\", 'Eisenhauer, E. A., P. Therasse, et al. (2009). \"New response evaluation criteria in solid tumours: revised', 'RECIST guideline (version 1.1). European journal of cancer 45(2): 228-247.', 'Eisenhofer, G., S. R. Bornstein, et al. (2004). \"Malignant pheochromocytoma: current status and', 'initiatives for future progress.\" Endocrine-related cancer 11(3): 423-436.', 'Favier, J., P. Igaz, et al. (2012). \"Rationale for anti-angiogenic therapy in pheochromocytoma and', \"paraganglioma.' Endocrine pathology 23(1): 34-42.\", \"Favier, J., P. F. Plouin, et al. (2002). 'Angiogenesis and vascular architecture in pheochromocytomas:\", \"distinctive traits in malignant tumors.' The American journal of pathology 161(4): 1235-1246.\", 'Fitoussi, O., M. Debled, et al. (1999). \"Brief report: Advanced paraganglioma: A role for chemotherapy?\"', 'Medical and pediatric oncology 33(2): 129-131.', 'Gimenez-Roqueplo, A. P., J. Favier, et al. (2001). \"The R22X mutation of the SDHD gene in hereditary', 'paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory', \"chain and activates the hypoxia pathway.' American journal of human genetics 69(6): 1186-1197.\", 'Gimenez-Roqueplo, A. P., J. Favier, et al. (2002). \"Functional consequences of a SDHB gene mutation in', 'an apparently sporadic pheochromocytoma.\" The Journal of clinical endocrinology and', 'metabolism 87(10): 4771-4774.', 'Glen, H., S. Mason, et al. (2011). \"E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell', 'migration and invasion.\" BMC cancer 11: 309.', 'Goldstein, R. E., J. A. O\\'Neill, Jr., et al. (1999). \"Clinical experience over 48 years with', 'pheochromocytoma.\" Annals of surgery 229(6): 755-764; discussion 764-756.', 'Gonias, S., R. Goldsby, et al. (2009). \"Phase II study of high-dose 311]metaiodobenzylguanidine', \"therapy for patients with metastatic pheochromocytoma and paraganglioma.' Journal of clinical\", 'oncology : official journal of the American Society of Clinical Oncology 27(25): 4162-4168.', 'Gottlieb, E. and I. P. Tomlinson (2005). \"Mitochondrial tumour suppressors: a genetic and biochemical', 'update.\" Nature reviews. Cancer 5(11): 857-866.', 'Gross, D. J., G. Munter, et al. (2006). \"The role of imatinib mesylate (Glivec) for treatment of patients', 'with malignant endocrine tumors positive for c-kit or PDGF-R.\" Endocrine-related cancer 13(2):', '535-540.', 'Hadoux, J., J. Favier, et al. (2014). \"SDHB mutations are associated with response to temozolomide in', 'patients with metastatic pheochromocytoma or paraganglioma.\" International journal of cancer', '135(11): 2711-2720.', 'Huang, H., J. Abraham, et al. (2008). \"Treatment of malignant pheochromocytoma/paraganglioma with', 'cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18', 'patients.\" Cancer 113(8): 2020-2028.', 'Huang, K. H., S. D. Chung, et al. (2007). \"Clinical and pathological data of 10 malignant', 'pheochromocytomas long-term follow up in a single institute.\" International journal of urology :', 'official journal of the Japanese Urological Association 14(3): 181-185.', 'Jasim Sina, C.A., Bible Keith (2016). Response to Lenvatinib in Progressive Metastatic Paraganglioma.', '98th Annual meeting og the Endocrine Society. Boston, MA: FRI 427.', 'Jimenez, C., M. E. Cabanillas, et al. (2009). \"Use of the tyrosine kinase inhibitor sunitinib in a patient', 'with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other', 'von Hippel-Lindau disease-related tumors.\" The Journal of clinical endocrinology and', 'metabolism 94(2): 386-391.', 'Jimenez, C., E. Rohren, et al. (2013). \"Current and future treatments for malignant pheochromocytoma', 'and sympathetic paraganglioma.\" Current oncology reports 15(4): 356-371.', 'Jirari, A., A. Charpentier, et al. (1999). \"A malignant primary cardiac pheochromocytoma.\" The Annals', 'of thoracic surgery 68(2): 565-566.', 'John, H., W. H. Ziegler, et al. (1999). \"Pheochromocytomas: can malignant potential be predicted?\"', 'Urology 53(4): 679-683.', 'Protocol Version Date:16Aug2018']['MC1575', '63', 'Amendment 2', 'Joshua, A. M., S. Ezzat, et al. (2009). \"Rationale and evidence for sunitinib in the treatment of malignant', 'paraganglioma/pheochromocytoma.\" The Journal of clinical endocrinology and metabolism', '94(1): 5-9.', 'Kruijtzer, C. M., J. H. Beijnen, et al. (2000). \"Successful treatment with paclitaxel of a patient with', 'metastatic extra-adrenal pheochromocytoma (paraganglioma). A case report and review of the', 'literature.\" Cancer chemotherapy and pharmacology 45(5): 428-431.', 'Kulke, M. H., K. Stuart, et al. (2006). \"Phase II study of temozolomide and thalidomide in patients with', 'metastatic neuroendocrine tumors.\" Journal of clinical oncology : official journal of the American', 'Society of Clinical Oncology 24(3): 401-406.', 'Lewi, H. J., R. Reid, et al. (1985). \"Malignant phaeochromocytoma. British journal of urology 57(4):', '394-398.', 'Liu, Q., G. Djuricin, et al. (1996). \"Tumor angiogenesis in pheochromocytomas and paragangliomas.\"', 'Surgery 120(6): 938-942; discussion 942-933.', 'Loh, K. C., P.A. Fitzgerald, et al. (1997). \"The treatment of malignant pheochromocytoma with iodine-', \"131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.'\", 'Journal of endocrinological investigation 20(11): 648-658.', 'Massey, V. and K. Wallner (1992). \"Treatment of metastatic chemodectoma.\" Cancer 69(3): 790-792.', 'Matsui, J., Y. Yamamoto, et al. (2008). \"E7080, a novel inhibitor that targets multiple kinases, has potent', 'antitumor activities against stem cell factor producing human small cell lung cancer H146, based', 'on angiogenesis inhibition.\" International Journal of Cancer 122(3): 664-671.', 'McNeil, A. R., B. H. Blok, et al. (2000). \"Phaeochromocytomas discovered during coronial autopsies in', 'Sydney, Melbourne and Auckland.\" Australian and New Zealand journal of medicine 30(6): 648-', '652.', 'Mertens, W. C., D. J. Grignon, et al. (1993). \"Malignant paraganglioma with skeletal metastases and', 'spinal cord compression: response and palliation with chemotherapy.\" Clinical oncology 5(2):', '126-128.', 'Nakane, M., S. Takahashi, et al. (2003). \"Successful treatment of malignant pheochromocytoma with', 'combination chemotherapy containing anthracycline.\" Annals of oncology : official journal of the', 'European Society for Medical Oncology / ESMO 14(9): 1449-1451.', 'Neumann, H. P., B. Bausch, et al. (2002). \"Germ-line mutations in nonsyndromic pheochromocytoma.\"', 'The New England journal of medicine 346(19): 1459-1466.', 'O\\'Riordain, D. S., W. F. Young, Jr., et al. (1996). \"Clinical spectrum and outcome of functional', \"extraadrenal paraganglioma.' World journal of surgery 20(7): 916-921; discussion 922.\", 'Oh, D. Y., T. W. Kim, et al. (2012). \"Phase 2 study of everolimus monotherapy in patients with', 'nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas.\" Cancer', '118(24): 6162-6170.', 'Ohji, H., I. Sasagawa, et al. (2001). \"Tumour angiogenesis and Ki-67 expression in', 'phaeochromocytoma. BJU international 87(4): 381-385.', 'Omura, M., J. Saito, et al. (2004). \"Prospective study on the prevalence of secondary hypertension among', 'hypertensive patients visiting a general outpatient clinic in Japan.\" Hypertension research :', 'official journal of the Japanese Society of Hypertension 27(3): 193-202.', 'Pacak, K., T. Fojo, et al. (2001). \"Radiofrequency ablation: a novel approach for treatment of metastatic', 'pheochromocytoma.\" Journal of the National Cancer Institute 93(8): 648-649.', 'Patel, S. R., D. J. Winchester, et al. (1995). \"A 15-year experience with chemotherapy of patients with', \"paraganglioma.' Cancer 76(8): 1476-1480.\", 'Pipas, J. M. and R. F. Krywicki (2000). \"Treatment of progressive metastatic glomus jugulare tumor', '(paraganglioma) with gemcitabine.\" Neuro-oncology 2(3): 190-191.', 'Pollard, P. J., J. J. Briere, et al. (2005). \"Accumulation of Krebs cycle intermediates and over-expression', 'of HIF 1alpha in tumours which result from germline FH and SDH mutations.\" Human molecular', 'genetics 14(15): 2231-2239.', 'Protocol Version Date:16Aug2018']\n\n###\n\n", "completion": "END"}